Stephan Martin

Stephan Martin is not mentioned in either of the provided news articles. The articles focus on the approval of a new weight loss pill, Orforglipron, by the FDA in the United States. This pill, developed by Eli Lilly, is intended for the treatment of obesity and weight-related conditions. The articles discuss the potential of Orforglipron to compete with existing injectable weight loss medications. The news is relevant due to the growing market for weight loss drugs and the increasing prevalence of obesity. The approval of a new oral medication offers a potentially more convenient alternative to injections for individuals seeking weight management solutions. The articles primarily address the pharmaceutical development and regulatory approval of Orforglipron, not any individual named Stephan Martin.